Oleg Gluz

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz, Ulrike Nitz, Matthias Christgen et al. · Journal of Clinical Oncology · 2016 · 357 citations

Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade

Philipp Müller, Matthias Kreuzaler, Tarik A. Khan et al. · Science Translational Medicine · 2015 · 328 citations

Breast Oncology, Immunology, Regulatory T Cells +17

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Breast Cancer Research and Treatment · 2017 · 183 citations · Full text

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Annals of Oncology · 2017 · 162 citations

Breast Oncology, Medicine, Neoadjuvant Dual Blockade +8

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Ulrike Nitz, Oleg Gluz, Michael Clemens et al. · Journal of Clinical Oncology · 2019 · 144 citations